The UK has one of the world’s leading pharmaceutical and life sciences industries, supported by strong scientific research, universities, clinical trials and advanced healthcare infrastructure. The country is home to major pharmaceutical companies as well as specialist businesses working in biotechnology, vaccines, advanced therapies and medicine manufacturing. 

The pharmaceutical sector is also an important contributor to UK research and innovation. In 2024, pharmaceutical R&D accounted for around £9.3 billion of UK business R&D spending, representing 17% of the total. 

From global giants such as AstraZeneca and GSK to specialist companies such as Hikma Pharmaceuticals, Oxford Biomedica and Shield Therapeutics, UK-linked pharmaceutical businesses cover a wide range of medical fields. Here are 10 notable pharmaceutical companies in the UK, including when they started, their founders or origins, and what they do.

AstraZeneca

Image Courtesy: AstraZeneca (Official Website)

AstraZeneca was established in 1999 through the merger of Sweden’s Astra AB and the UK’s Zeneca Group PLC. Therefore, it does not have one individual founder in the traditional sense. Astra AB itself was founded in 1913 by a group of doctors and apothecaries, while Zeneca emerged from the pharmaceutical business of Imperial Chemical Industries (ICI). The 1999 merger brought these two pharmaceutical businesses together to create AstraZeneca.

AstraZeneca is a global, science-led pharmaceutical and biopharmaceutical company headquartered in Cambridge, UK. The company researches, develops and commercialises prescription medicines for serious and chronic diseases. Its major therapeutic areas include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunological conditions, and rare diseases. AstraZeneca places a strong emphasis on research and development, using scientific research, biotechnology and advanced medicine development to create new treatments. Its medicines are used by patients across many countries, making it one of the world’s major pharmaceutical companies.

GSK

Image Courtesy: GSK (Official Website)

GSK, originally known as GlaxoSmithKline, was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham. There is therefore no single individual founder of modern GSK. The company has a much older heritage, however, with predecessor businesses tracing their histories back centuries. GSK’s official history identifies the origins of its heritage with businesses such as Plough Court Pharmacy, while the modern GSK was created when the two major pharmaceutical companies merged in December 2000. 

GSK is a major global biopharmaceutical company headquartered in London. It discovers, develops and manufactures medicines and vaccines designed to prevent and treat diseases. The company has particular expertise in respiratory diseases, infectious diseases, HIV, immunology and inflammation, and oncology. GSK also has a major vaccine business, developing and supplying vaccines against a range of infectious diseases. Its work combines pharmaceutical research, vaccine science, clinical development and large-scale manufacturing. The company’s overall objective is to use science and innovation to help prevent disease and improve health outcomes for patients worldwide.

Hikma Pharmaceuticals

Image Courtesy: Hikma Pharmaceuticals (Official Website)

Hikma Pharmaceuticals was founded in 1978 by Samih Darwazah in Jordan. Unlike companies formed through mergers, Hikma has a clearly identified founder. Samih Darwazah established the company with the aim of developing a pharmaceutical business that could provide quality medicines to patients, and the company gradually expanded from Jordan into the wider Middle East and North Africa, Europe and North America. Hikma’s own history identifies 1978 as the year it was founded and Samih Darwazah as its founder. 

Today, Hikma is a global pharmaceutical company that develops, manufactures and supplies generic, branded and specialty medicines. Its operations are organised around three main businesses: Injectables, Hikma Rx and Branded medicines. The company supplies more than 825 products across North America, Europe and the Middle East and North Africa. Hikma is particularly well known for injectable medicines and specialty pharmaceutical products, while also providing affordable generic medicines. Its overall purpose is to make high-quality medicines accessible to the people who depend on them.

Haleon

Image Courtesy: Haleon (Official Website)

Haleon became an independent company in 2022. It does not have a single founder because it was created through the demerger of GSK’s Consumer Healthcare business. The demerger was completed on 18 July 2022, when Haleon became an independently listed consumer healthcare company. Although the Haleon name and independent company date from 2022, its business has a much longer heritage, with roots extending back to an apothecary shop opened by Silvanus Bevan in London in 1715. 

Haleon is a global consumer healthcare company focused on everyday health rather than traditional prescription pharmaceuticals. It develops, markets and sells products that people can use to manage common health needs. Its major categories include oral health, pain relief, respiratory health, digestive health, and vitamins, minerals and supplements. Its portfolio includes well-known brands such as Sensodyne, Panadol and Voltaren. Haleon operates in more than 170 markets and focuses on combining scientific research with consumer understanding to develop accessible products that help people take care of their everyday health. 

Indivior

Image Courtesy: Indivior (Official Website)

Indivior became an independent pharmaceutical company in 2014 following its demerger from Reckitt Benckiser Group. It does not have a traditional individual founder because the business originated as a pharmaceutical division within Reckitt Benckiser. The company’s history can be traced back to 1994, when Reckitt Benckiser established its Buprenorphine Business Group to develop treatments for opioid dependence. Indivior PLC was incorporated in September 2014 and became an independent business following the demerger in December 2014. 

Indivior specialises in addiction medicine, with a particular focus on treatments for opioid use disorder (OUD). The company develops medicines intended to help people living with addiction and related chronic conditions. Its important products include SUBOXONE and SUBLOCADE, which are used in the treatment of opioid dependence. Indivior has played a role in promoting evidence-based approaches to addiction treatment and in expanding access to treatment beyond highly controlled clinical environments. The company is now headquartered in the United States following its 2026 redomiciliation, so while it has strong UK corporate origins, it should not be described today as a UK-headquartered pharmaceutical company.

Dechra Pharmaceuticals

Image Courtesy: Dechra Pharmaceuticals (Official Website)

Dechra Pharmaceuticals was established in 1997 and celebrated its 25th anniversary in 2022. Rather than being associated with one well-known individual founder, Dechra developed from a management buyout of the veterinary pharmaceutical business of Lloyds Chemists. Over more than two decades, the company expanded from its UK origins into an international animal-health business. Dechra describes itself as having grown into a global leader in veterinary pharmaceuticals since its establishment in 1997. 

Dechra specialises in veterinary pharmaceuticals and animal health rather than medicines for humans. The company develops, manufactures and supplies medicines and related products used by veterinary professionals to treat animals. Its products cover everyday veterinary needs as well as treatments for more specialised and less common diseases. Dechra works closely with veterinarians and provides scientific information, training and support alongside its medicines. Its business serves both companion animals and animals in other veterinary settings, making it an important specialist player in the international animal-health industry. 

Oxford Biomedica

Image Courtesy: Oxford Biomedica (Official Website)

Oxford Biomedica, commonly known as OXB, was founded in 1995 as a spin-out from the University of Oxford. Because it originated as a university spin-out rather than a conventional privately founded company, it is not generally attributed to one individual founder. The company was established with the aim of using advances in cell and gene therapy to transform medicine and has subsequently developed more than 30 years of expertise in this field. 

Oxford Biomedica is a specialised viral-vector contract development and manufacturing organisation (CDMO). Instead of mainly selling finished medicines directly to consumers, it works with biopharmaceutical companies to help them develop, scale up and manufacture products used in cell and gene therapies. Its capabilities include the development and manufacture of viral vectors such as lentiviral vectors and other technologies used to deliver genetic material. OXB provides services throughout the development process, from early-stage research and process development through to large-scale, GMP-compliant commercial manufacturing. This makes the company particularly important to the growing cell and gene therapy industry. 

ADVANZ PHARMA

Image Courtesy: ADVANZ PHARMA (Official Website)

ADVANZ PHARMA is a global specialty pharmaceutical business whose modern corporate identity dates from 2018, when Concordia International was rebranded as ADVANZ PHARMA. Therefore, it does not have a single founder in the same way as a company such as Hikma. The modern organisation developed through predecessor businesses, acquisitions and corporate restructuring. Company documentation records the rebranding of Concordia International to ADVANZ PHARMA in 2018. 

ADVANZ PHARMA focuses on specialty, hospital and rare-disease medicines. Its portfolio includes innovative medicines, biosimilars, specialty generics and established originator brands. The company works across a wide range of therapeutic areas, including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, central nervous system conditions and rare diseases. Its business model focuses strongly on improving access to important medicines, particularly medicines that may have limited availability or require specialist knowledge. ADVANZ PHARMA combines its pharmaceutical portfolio with partnerships and international commercial capabilities to supply medicines across multiple markets. 

Verona Pharma

Image Source: Merck Official Website – Verona Pharma Acquisition (Official Website)

Verona Pharma was incorporated in February 2005 under the name Isis Resources plc. In 2006, the company acquired Rhinopharma Limited and changed its name to Verona Pharma plc. Because the business was incorporated as a corporate entity rather than founded around one clearly identified entrepreneur, it is more accurate to describe its beginning through its incorporation and subsequent development rather than naming a single founder. 

Verona Pharma is a biopharmaceutical company focused on respiratory diseases, particularly chronic obstructive pulmonary disease, or COPD. The company’s major medicine is Ohtuvayre (ensifentrine), a respiratory treatment developed to address the needs of patients with COPD. Verona has concentrated its research and development activities on novel therapies that can provide new treatment options for people living with chronic respiratory conditions. The company has historically had UK roots and significant operations in the United States, and its corporate development has increasingly focused on the U.S. respiratory medicines market. Verona Pharma became a subsidiary of Merck & Co. in 2025, further changing its position within the global pharmaceutical industry.

Shield Therapeutics

Image Courtesy: Shield Therapeutics (Official Website)

Shield Therapeutics is a specialty pharmaceutical company focused on iron deficiency and iron-deficiency anaemia. Its business developed from predecessor pharmaceutical ventures, including SHG Therapeutics, which was co-founded by Carl Sterritt in 2008. Sterritt subsequently served as CEO and played a major role in developing the business and its commercialisation strategy. Therefore, when discussing the company’s origins, it is more accurate to refer to Carl Sterritt as a co-founder of the predecessor business rather than simply describing him as the sole founder of Shield Therapeutics. 

Shield Therapeutics focuses on developing and commercialising treatments that address iron deficiency, particularly in patients who may need an alternative to conventional oral iron treatments. Its key medicine is ferric maltol, marketed under names including ACCRUFeR in the United States and Feraccru in other markets. The company works through direct commercial operations and licensing partnerships in different countries. Its main objective is to improve the treatment of iron deficiency and iron-deficiency anaemia by increasing access to an effective oral iron therapy and expanding its availability across international healthcare markets.

Conclusion

The UK pharmaceutical industry plays an important role in global healthcare, medical research and drug development. Companies such as AstraZeneca and GSK have established the country as a major centre for innovative medicines and vaccines, while businesses such as Hikma Pharmaceuticals, Oxford Biomedica and Indivior contribute expertise in generics, advanced therapies and specialist treatments.

The industry is also becoming increasingly focused on biotechnology, personalised medicine, gene and cell therapies, digital technologies and sustainable healthcare. With strong research institutions, skilled professionals and continued investment in life sciences, the UK remains an important pharmaceutical market and a significant contributor to the development of new healthcare solutions.

Frequently Asked Questions

Which is the largest pharmaceutical company in the UK?

AstraZeneca is one of the largest UK-headquartered pharmaceutical companies and a major global pharmaceutical business.

What are the top pharmaceutical companies in the UK?

Major names include AstraZeneca, GSK, Hikma Pharmaceuticals, Indivior, Dechra Pharmaceuticals, Oxford Biomedica and Advanz Pharma.

Where is AstraZeneca headquartered?

AstraZeneca has its global headquarters in Cambridge, England.

Where is GSK headquartered?

GSK is headquartered in London, United Kingdom.

What is the UK pharmaceutical industry known for?

It is particularly known for pharmaceutical R&D, innovative medicines, vaccines, biotechnology and advanced therapies.

Are there biotechnology companies in the UK?

Yes. The UK has a substantial biotechnology sector, including companies working on gene therapy, cell therapy and other advanced medicines.

Which UK pharmaceutical company specialises in generic medicines?

Hikma Pharmaceuticals is particularly known for generic and injectable medicines.

Which UK company focuses on gene and cell therapies?

Oxford Biomedica specialises in technologies and manufacturing services used in cell and gene therapies.

Does the UK manufacture veterinary medicines?

Yes. Dechra Pharmaceuticals is a prominent company specialising in veterinary pharmaceuticals.

Is the UK a major pharmaceutical market?

Yes. The UK is an important global life-sciences market, supported by established pharmaceutical companies, universities, research institutions and biotechnology businesses.